Isotype-specific Retinoic Acid receptor (RARβ) Antagonists for the Treatment and Prevention of Lung Disease
Section: For Industry
Category(ies): Viruses, Chronic and Infectious Diseases
Reference #: MADO433805
OTC Contact: Ruchika Nijhara, Ph.D. (Directory Information | Send a Message)
Description
The present invention is directed to methods of treating an age-related loss of lung function. The invention describes use of an estrogen and/or retinoid that specifically binds to Retinoid-Acid- Receptor (RAR).
Applications
- Treating pulmonary diseases such as COPD, asthma etc
- Treating the age-related loss of alveoli or gas-exchange.
- Diagnostic tool to identify genetic or acquired defect involving RAR function.
- Specific targeting of alveolar formation (using isotype-specific receptor agonist) can reduced the undesired side effects causing by non-specific signaling.
- Use of RARβ agonists when used in combination with All-trans-Retinoic Acid (ATRAs) can reduce the effective doses of ATRAs as well may result in synergistic therapeutic effect.
Advantages
Stage of Development
Stage of Development: Studies in mice demonstrate that alveolus formation is promoted in vivo by inhibition of RARβ receptor.
Relevant Publications
- "Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats", Massaro et al, Nature Medicine, vol. 3, No. 6,675-677 (1997).
- "Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats", Massaro et al, Am. J. Physiol., 270, L305-L310 (1996).
Patent Status
U.S. patents 6,303,648 “Composition and Methods for the Treatment and Prevention of Lung Disease” Issued on October 19, 2001. US Patent Application # 11/978,166 pending.
